Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Evaluation of Clinical, Immunological, Morphological, Molecular and Genetic Characteristics of Patients With Limb-girdle Muscular Dystrophy Type R2 (Type 2B) in the Russian Federation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04824040
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:39.227318+00:00
Published At
2025-06-27T00:00:00+00:00
Record Updated At
2025-06-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Dysferlinopathy", "Miyoshi Myopathy", "LGMDR2", "DMAT"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-27"
protocolSection.identificationModule.nctId
"NCT04824040"
protocolSection.identificationModule.officialTitle
"Evaluation of Clinical, Immunological, Morphological, Molecular and Genetic Characteristics of Patients With Limb-girdle Muscular Dystrophy Type R2 (Type 2B) in the Russian Federation"
protocolSection.statusModule.overallStatus
"ENROLLING_BY_INVITATION"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Dysferlinopathy (protocolSection.conditionsModule.conditions)
  • Miyoshi Myopathy (protocolSection.conditionsModule.conditions)
  • LGMDR2 (protocolSection.conditionsModule.conditions)
  • DMAT (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.